Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92385Research ArticleRol' amlodipina v sovremennom lechenii serdechno-sosudistykh zabolevaniy i snizhenii assotsiiruemoy s nimi smertnostiGorokhovskayaG. N-PetinaM. M-MartynovA. I-1502200792919628122021Copyright © 2007, Consilium Medicum2007[Kloner R.A et al. Sex - and age - related antihypertensive effect of amlodipine. Am J Card 1996; 77: 713-22.][Маколкин В.И. Антагонисты кальция в лечении артериальной гипертензии РМЖ. 2003; 11 (9).][Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика забол. и укрепление здоровья. 2001; 2: 3-7.][Fleckenstein A, Tritthart H, Fleckenstein B et al. Eine neue Gruppe kompetitiver Ca++-Antagonisten (Iproveratril, D6000, Prenylamin) mit starken Hemeffekten auf die elektromekanische Koppelung im Warmbluter - myocard. Pflugers Arch 1969; 307: R25.][Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J Physiol Lond 1882; 4: 29-42.][Марцевич С.Ю. Антагонисты кальция - принципы терапии в свете данных доказательных исследований. РМЖ. 2003; 11 (27).][Pahor M, Psaty B, Alderman M. Health outcomes associated with calcium antagonists compared with other first - line antihypertensive therapies: a meta - analysis of randomized controlled trials. Lancet 2000; 356: 1949-54.][Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE - inhibitors, calcium antagonists, and other blood - pressure - lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 200; 355: 1955-64.][Brown M.J, Palmer C.R, Castaigne A et al. Morbidity and mortality in patients randomised to double - blind treatment with a long - acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.][Kolloch R.E. INVEST: Results of combined strategies to control blood pressure. Clin Cardiol 2001; 24 (Suppl. V): 12-3.][The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.][Watts R.W et al. A placebo - controlled comparison of diltiazem and amlodipine monotherapy in essentional hypertension using 24-h ambulatory monitoring. Blood Press 1998; 7 (1): 25-30.][Maior Outcomes in High - Risk Hypertensive Patients Randomised to Angiotensin - Converting Ensyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMMA 2002; 288 (23): 2981-98.][Lipicky R. Trough/peak ratio: the rational behind the United States FDA recommendations. J Hypertens 1994; 12 (suppl. 8): S17-9.][Zannad et al. Trough/peak ratios of ACE inhibitors and Ca antagonists. Am J Hypertens 1996; 9 (7).][Малышева Е.А. Влияние амлодипина на массу миокарда левого желудочка и показатели центральной гемодинамики у больных с артериальной гипертонией и атеросклерозом сонных артерий. Клин. фармакол. и тер. 1997; 6 (3): 2-4.][Detry J.M. Amlodipine and the total ischemic burden: Circadian Anti - Ischemia Program in Europe (CAPE) trial - Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24-30.][Nessen S.E, Tuzcu E.M, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA 2004; 292 (18): 2217-26.][Gastell W, Anderson K. Apopulation at risk prevalence of high cholesterol levels in the hypertensive patients in the Framingham study. Am J Med 1986; 2 (80): 23-32.][Van Zwienten A. Protective affect of calcium antagonists in different organs and tissues. Am Heart J 1993; 2 (125): 223-6.][Сидоренко Б.А., Преображенский Д.В. Диапазон применения современных антагонистов кальция при сердечно - сосудистых заболеваниях. Тер. арх. 1998; 2: 80-4.][Гуревич М.А. Спорные вопросы использования антагонистов кальция при ишемической болезни сердца. Рос. кардиол. журн. 1997; 2: 3-12.][Simon A, Gariepy J, Moyse D et al. Differential effect of nifedipine and co - amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-54.][Montro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410-3.][Reichardt B. Antiatherosclerotic effect of lacidipine. Pharmocotherap 1995; 6: 37-43.][Mason R.P, Walter M.F, Trumbore M.W et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1990; 31: 275-81.][Buington R.P, Chen J, Furberg C.D, Pitt B. Effect of amlodipine on cardiovascular events and procedures (abstr). J Am Coll Cardiol 1999; 31 (Suppl. A): 314 A.][Кобалава Ж.Д. Ранний, стабильный контроль АД - гарант улучшения прогноза при артериальной гипертонии высокого риска: результаты мега - исследования VALUE. РМЖ. 2004; 12 (15): 922-6.][Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.]